CRNX
Crinetics Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$83.87+0.01%
Price as of Jul 20, 2026
CRNX growth
Crinetics Pharmaceuticals, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +2277.5%
- EBITDA
- -37.1%
- EBIT
- -44.9%
- EPS
- -34.6%
- Free cash flow
- -58.1%
- Operating cash flow
- -58.3%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +17.6%
- EBITDA
- -56.0%
- EBIT
- -52.5%
- Net income
- -55.9%
- EPS
- -34.1%
- Free cash flow
- -67.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.